Dr. Chloé Fischer

Pathologist · Kyoto University Hospital · Japan (JP) · Oncology

Tier 3STK-0019GoodOwner MSL JWJames Whitfield

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: SCLC, NSCLC
Scientific interests: PD-L1 biomarkersBrain metastases
Engagement preference: Either
Advisory boards: 1
Publications: 12
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 3: 1 per year (assumption)

Last engaged: 25 Jan 2026 (233 days ago)
Next planned contact: 25 Jan 2027
Last 6 months vs target: 0%
0 of 1 expected engagements

Insights from this stakeholder (0)

No insights captured from engagements with this stakeholder.

Engagement history (2)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
15 Sept 2026	Scientific exchange	Virtual	James Whitfield	Vantrexa	Elderly / ECOG 2 patientsComparator checkpoint monotherapy+1	0	—	Draft	ENG-0093
25 Jan 2026	Scientific exchange	In person	James Whitfield	Vantrexa	Chemotherapy-free first line	0	—	Reviewed	ENG-0060

Timeline

15 Sept 2026
Scientific exchange
Elderly / ECOG 2 patients, Comparator checkpoint monotherapy, Chemotherapy-free first line
25 Jan 2026
Scientific exchange
Chemotherapy-free first line

Related stakeholders (7)

Kyoto University Hospital

Dr. Chloé Meyer
Pathologist
Tier 2
Dr. Emiko Quinn
Radiation oncologist
Tier 3
Dr. Farah Jensen
Radiation oncologist
Tier 1
Dr. Andrea Ueda
General neurologist
Tier 1
Dr. Farah Meyer
General neurologist
Tier 3
Dr. Hiroshi Yamamoto
Primary care physician
Tier 3
Dr. Rosa Garcia
General neurologist
Tier 3